pivotal: search

Intellect Neurosciences, Inc. obtains Pivotal European Patent related to monoclonal antibody passive immunization treatment of Alzheimer's Disease

Intellect Neurosciences, Inc. obtains Pivotal European Patent related to monoclonal antibody passive immunization treatment of Alzheimer's Disease

CRM 6.0 from Pivotal, Sales Simplicity in Canada, Cincom Acquire, Sales-i in U.S., Infogain and Red Hat, Brett Favre

CRM 6.0 from Pivotal, Sales Simplicity in Canada, Cincom Acquire, Sales-i in U.S., Infogain and Red Hat, Brett Favre

Intellect Neurosciences, Inc. Obtains Pivotal European Patent

Intellect Neurosciences, Inc. Obtains Pivotal European Patent Related To Monoclonal Antibody Passive Immunization Treatment Of Alzheimer's Disease

Intellect Neurosciences, Inc. Obtains Pivotal European Patent Related To Monoclonal Antibody Passive Immunization Treatment Of Alzheimer's Disease

Intellect Neurosciences, Inc. Obtains Pivotal European Patent Related To Monoclonal Antibody Passive Immunization Treatment Of Alzheimer's Disease

Pivotal Games shuts its doors

Staff at Conflict series developer notified of closure today; small team of specialists will be kept by SCi

Intellect Neurosciences, Inc. Obtains Pivotal European Patent Related to Monoclonal Antibody Passive Immunization Treatment Of Alzheimer's Disease

NEW YORK, July 31, 2008 /PRNewswire-FirstCall/-- Intellect Neurosciences, Inc. announced today it has obtained a European patent relating to the Company's ANTISENILIN(R) monoclonal antibody platform for the treatment of Alzheimer's disease. The claims of the issued patent cover the ANTISENILIN(R) "free-end specific" antibodies that bind to beta amyloid and use of the antibodies in preventing or inhibiting the progression of Alzheimer's disease. The technology is designed to promote the clearance of beta amyloid which accumulates to reach toxic concentrations in the brains of Alzheimer's patients while reducing the potential for adverse side-effects. Importantly, such drugs avoid binding and thereby potentially interfering with the functions of the Amyloid Precursor Protein, which is an important physiological regulator in the body implica

Intellect Neurosciences, Inc. Obtains Pivotal European Patent Related To Monoclonal Antibody Passive Immunization Treatment Of Alzheimer's Disease

NEW YORK, July 31 /PRNewswire-FirstCall/-- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS) announced today it has obtained a European patent relating to the Company's ANTISENILIN(R) monoclonal antibody platform for the treatment of Alzheimer's disease. The claims of the issued patent cover the ANTISENILIN(R) "free-end specific" antibodies that bind to beta amyloid and use of the antibodies in preventing or inhibiting the progression of Alzheimer's disease. The technology is designed to promote the clearance of beta amyloid which accumulates to reach toxic concentrations in the brains of Alzheimer's patients while reducing the potential for adverse side-effects. Importantly, such drugs avoid binding and thereby potentially interfering with the functions of the Amyloid Precursor Protein, which is an important physiological regulato

Intellect Neurosciences, Inc. Obtains Pivotal European Patent Related To Monoclonal Antibody Passive Immunization Treatment Of Alzheimer's Disease

PRNewswire-FirstCall/-- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS) announced today it has obtained a European patent relating to the Company's ANTISENILIN(R) monoclonal antibody platform for the treatment of Alzheimer's disease. The claims of the issued patent cover the ANTISENILIN(R) "free-end specific" antibodies that bind to beta amyloid and use of the antibodies in preventing or inhibiting the progression of Alzheimer's disease. The technology is designed to promote the clearance of beta amyloid which accumulates to reach toxic concentrations in the brains of Alzheimer's patients while reducing the potential for adverse side-effects. Importantly, such drugs avoid binding and thereby potentially interfering with the functions of the Amyloid Precursor Protein, which is an important physiological regulator in the body impl

Intellect Neurosciences, Inc. Obtains Pivotal European Patent Related To Monoclonal Antibody Passive Immunization Treatment Of Alzheimer's Disease

NEW YORK, July 31, 2008 /PRNewswire via COMTEX/ -- NEW YORK, July 31 /PRNewswire-FirstCall/-- Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Obtains Pivotal European Patent Related ...

Hier finden Sie Nachrichten zu Ihrem Suchbegriff - Sie können den Zeitraum angeben oder auch Suchbegriffe kombinierenErweiterte Suche |

Intellect Neurosciences, Inc. Obtains Pivotal European Patent Related To Monoclonal Antibody Passive Immunization Treatment Of Alzheimer's Disease

NEW YORK, July 31 /PRNewswire-FirstCall/-- Intellect Neurosciences, Inc. announced today it has obtained a European patent relating to the Company's ANTISENILIN(R) monoclonal antibody platform for the treatment of Alzheimer's disease. The claims of the issued patent cover the ANTISENILIN(R) "free-end specific" antibodies that bind to beta amyloid and use of the antibodies in preventing or inhibiting the progression of Alzheimer's disease. The technology is designed to promote the clearance of beta amyloid which accumulates to reach toxic concentrations in the brains of Alzheimer's patients while reducing the potential for adverse side-effects. Importantly, such drugs avoid binding and thereby potentially interfering with the functions of the Amyloid Precursor Protein, which is an important physiological regulator in the body implicated in

Intellect Neurosciences, Inc. Obtains Pivotal European Patent Related To Monoclonal Antibody Passive Immunization Treatment Of Alzheimer's Disease

NEW YORK, July 31 /PRNewswire-FirstCall/-- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS) announced today it has obtained a European patent relating to the Company's ANTISENILIN(R) monoclonal antibody platform for the treatment of Alzheimer's disease. The claims of the issued patent cover the ANTISENILIN(R) "free-end specific" antibodies that bind to beta amyloid and use of the antibodies in preventing or inhibiting the progression of Alzheimer's disease. The technology is designed to promote the clearance of beta amyloid which accumulates to reach toxic concentrations in the brains of Alzheimer's patients while reducing the potential for adverse side-effects. Importantly, such drugs avoid binding and thereby potentially interfering with the functions of the Amyloid Precursor Protein, which is an important physiological regulato

Intellect Neurosciences, Inc. Obtains Pivotal European Patent Related To Monoclonal Antibody Passive Immunization Treatment Of Alzheimer's Disease

NEW YORK, July 31 /PRNewswire-FirstCall/-- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS) announced today it has obtained a European patent relating to the Company's ANTISENILIN(R) monoclonal antibody platform for the treatment of Alzheimer's disease. The claims of the issued patent cover the ANTISENILIN(R) "free-end specific" antibodies that bind to beta amyloid and use of the antibodies in preventing or inhibiting the progression of Alzheimer's disease. The technology is designed to promote the clearance of beta amyloid which accumulates to reach toxic concentrations in the brains of Alzheimer's patients while reducing the potential for adverse side-effects. Importantly, such drugs avoid binding and thereby potentially interfering with the functions of the Amyloid Precursor Protein, which is an important physiological regulato

Protein made by fat cells may increase risk of heart attack in older adults

Adiponectin, a protein produced by fat cells, may play a pivotal and counterintuitive role in cardiovascular health for older Americans according to a new study accepted for publication in the Journal of Clinical Endocrinology & Metabolism (JCEM).

Shuttle Astronauts Eager for Risky Mission to Hubble

Seven NASA astronauts are eagerly looking forward to a risky, but pivotal, shuttle flight to the Hubble Space Telescope this fall.

Star Wars video game bridges gap between films

Consider it "Star Wars III and a Half" - complete with a pivotal plot twist. When LucasArts releases "Star Wars: The Force Unleashed" on Sept. 16, the video game will serve as George Lucas' official median between 2005's "Star Wars: Episode III - Revenge of the Sith" and 1977's "Star Wars: Episode IV - A New Hope." In the game, players become Darth Vader's secret apprentice and use The Force to hunt the remaining Jedi.

A dance of environment and economics in the Florida Everglades

The biomass power plant that is part of the Florida Crystals sugar refinery could play a pivotal role in a plan to revive water flow in the Everglades.

Apple's iTunes Store pays tribute to Isaac Hayes

When Isaac Hayes died last week, the world lost an iconic figure of African American culture. Perhaps best known as his music for Shaft, Hayes also played a pivotal role in the success of Stax Records, what many consider to be one of the two original major Soul record labels. Naturally, he also played the character of Chef in the TV show South Park.

China's Olympic ambitions battered

In this July 25 file photo, people queue up for the last batch of Olympic tickets outside of Shanghai Stadium in Shanghai. China's hopes that the Olympics would be a pivotal moment in national glory and global acceptance have been battered, as unforeseen events collided with its grand ambitions.

Former Google Executive and New Media Expert Charley Cassell Joins Vibes Media as Chief Financial Officer

CHICAGO - (Business Wire) Vibes Media, the market-leading interactive mobile marketing company, announced today the appointment of Charley Cassell as Chief Financial Officer. Cassell held several senior positions at leading internet companies before joining Vibes. In his previous role as CFO of Chicago-based internet company FeedBurner, he played a pivotal role in the company

Former Google Executive and New Media Expert Charley Cassell Joins Vibes Media as Chief Financial Officer

CHICAGO, July 2, 2008 -- Vibes Media, the market-leading interactive mobile marketing company, announced today the appointment of Charley Cassell as Chief Financial Officer. Cassell held several senior positions at leading internet companies before joining Vibes. In his previous role as CFO of Chicago-based internet company FeedBurner, he played a pivotal role in the company’s acquisition by Google and managed the integration of sales, business operations and financial processes, helping to sustain consistent quarterly growth.

Former Google Executive and New Media Expert Charley Cassell Joins Vibes Media as Chief Financial Officer

CHICAGO--(BUSINESS WIRE)--July 2, 2008--Vibes Media, the market-leading interactive mobile marketing company, announced today the appointment of Charley Cassell as Chief Financial Officer. Cassell held several senior positions at leading internet companies before joining Vibes. In his previous role as CFO of Chicago-based internet company FeedBurner, he played a pivotal role in the company’s acquisition by Google and managed the integration of sales, business operations and financial processes, helping to sustain consistent quarterly growth.

Novelos Therapeutics Receives 6th U.S. Patent

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos was issued U.S. Pat. No. 7,371,411 by the U.S. Patent and Trademark Office extending the composition and method of use claims relating to NOV-002, Novelos' lead compound in an ongoing pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track. NOV-002 has also demonstrated positive results in Phase 2 trials for other oncology indications.

dpreview seeks ninja web-developers

Impressed by the lens data presentation widget? Think you can do better? dpreview.com is looking for standards-savvy, photography-loving web developers to form a new web development team. Impress your friends and confound your enemies by spending your days building cool features for a massive (and growing) community. It'll mean working in London (UK), and it's an opportunity to play a pivotal role in the future of the world's leading digital photography website.

Novelos Therapeutics Receives 6th U.S. Patent

NEWTON, Mass.--(BUSINESS WIRE)--June 30, 2008 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos was issued U.S. Pat. No. 7,371,411 by the U.S. Patent and Trademark Office extending the composition and method of use claims relating to NOV-002, Novelos' lead compound in an ongoing pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track. NOV-002 has also demonstrated positive results in Phase 2 trials for other oncology indications.

Search took 0.02 seconds.